XingImaging
XingImaging is a neuroimaging CRO providing radioligand development, Phase 1-4 clinical trial imaging, and multi-center core lab services to pharmaceutical, biotech, and academic research sponsors focused on neurodegenerative and neuropsychiatric disorders.
- Company typePrivate
- Founded2018
- HeadquartersMadison, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What XingImaging does
XingImaging is a US-based contract research organization (CRO) providing clinical imaging services for drug development trials focused on neurodegenerative and neuropsychiatric disorders. Founded in 2018 by four internationally-recognized clinical neuroscience experts (Drs. Tamagnan, Chan, Marek, and Seibyl), the company operates from a 24,000+ sq ft research facility in New Haven, Connecticut, with over 40 staff organized into Clinical, Chemistry, and Imaging Sciences divisions supported by Regulatory Affairs, Quality Assurance, Imaging and Data Management, IT, and Business Operations. Its service portfolio spans the pre-clinical to Phase 4 spectrum, including radioligand development and GMP manufacturing, Phase 1-4 clinical trial design and implementation, and multi-center imaging core lab services, with emphasis on investigational radiotracers and quantitative imaging outcome measures for disease mechanism and progression assessment.
The company's underlying technology stack centers on PET, SPECT-CT, and MRI scanners paired with custom radiopharmaceuticals and scintigraphic biomarkers. It operates a proprietary SaaS imaging management application (SliceVault) hosted in Microsoft Azure for image and metadata management across multi-site studies, and uses a proprietary translational research model for rapid radioligand screening from radiochemistry through pre-clinical and human proof-of-concept. The leadership team includes internationally-recognized experts who have collectively evaluated over 70 CNS PET and SPECT imaging agents in human studies and submitted more than 35 INDs as physician sponsor.
XingImaging generates revenue through professional services contracts (quote-based pricing tied to study scope, duration, and participant numbers) with pharmaceutical companies, biotech firms, and academic research sponsors. It serves a horizontally-segmented customer base requiring specialized neuroimaging expertise, including the Alzheimer's Tau Platform (ATP) Phase II trial as Imaging Core Lab (up to 750 participants across approximately 78 sites) and the Parkinson's Progression Markers Initiative (PPMI). Since a 2023 merger with MITRO Biotech Co., Ltd., XingImaging operates as part of the MITRO group, which also includes Mitro Imaging UK LLC and Mitro Imaging France LLC, providing a multi-jurisdiction footprint.
XingImaging firmographics
Firmographics- Name
- XingImaging
- Legal name
- XingImaging, LLC
- Website
- https://xingimaging.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- XingImaging is a neuroimaging CRO providing radioligand development, Phase 1-4 clinical trial imaging, and multi-center core lab services to pharmaceutical, biotech, and academic research sponsors focused on neurodegenerative and neuropsychiatric disorders.
- Ownership category
- akta.pro rank
XingImaging industry classification
Industry- Product category
- Clinical Trial Imaging Services
- NAICS
- Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Imaging Core Labs & Clinical Endpoint Adjudication (HLAGAEAH)
- akta.pro secondary industries
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where XingImaging is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
XingImaging business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Clinical Imaging Services: Services across pre-clinical and clinical spectrum including radioligand development and manufacturing, design and implementation of Phase 1 to Phase 4 clinical trials, and customized clinical imaging site coordination and management in multi-site imaging studies. Revenue generated through contract research services to pharmaceutical companies and research sponsors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
XingImaging product offering
Product offeringCore offering
XingImaging is a contract research organization that provides neuroimaging services for drug development and clinical research, specializing in the application of PET imaging with custom radiopharmaceuticals and radioligands for neurodegenerative and neuropsychiatric disorders. Its offerings span radioligand development and manufacturing, design and implementation of Phase 1 through Phase 4 clinical trials, and multi-center imaging core lab coordination, with a strong emphasis on investigational radiotracers and quantitative imaging outcome measures.
Product overview
XingImaging is a neuroimaging services company that offers a comprehensive suite of services for drug development and clinical research focused on neurodegenerative and neuropsychiatric disorders. The company's portfolio centers on PET imaging services using scintigraphic biomarkers and investigational radiotracers. Key offerings include: Radioligand Development and Manufacturing (radiopharmaceutical development and GMP production), Clinical Trial Design and Implementation (Phase 1-4 trials), and Multi-Center Imaging Core Lab Services (site coordination and management). The company also provides Translational Research Services for early drug development. As of 2026, XingImaging serves as the Imaging Core Lab for the Alzheimer's Tau Platform (ATP) Phase II clinical trial. Founded in 2018 and headquartered in New Haven, CT as a MITRO company, XingImaging operates over 24,000 sq ft of research space with more than 40 staff members organized into Clinical, Chemistry, and Imaging Sciences divisions.
Differentiator
Problem solved
Functional benefit
Products and services
- Radioligand Development and Manufacturing
- Clinical Trial Design and Implementation Services
- Multi-Center Imaging Core Lab Services
- Translational Research Services
Quantifiable outcome
- Over 70 CNS PET and SPECT imaging agents evaluated in human studies for neurologic and psychiatric conditions
- +3 more outcomes
Companies that use XingImaging
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
XingImaging technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
XingImaging partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- MITRO Biotech Co., Ltd.coreIn 2023, XingImaging and MITRO Biotech Co., Ltd. each highly recognized for drug development and imaging solutions joined forces to provide services across the pre-clinical and clinical spectrum. The partnership enables radioligand development and manufacturing, design and implementation of Phase 1 to Phase 4 clinical trials, and customized clinical imaging site coordination in multi-site imaging studies.
- Alzheimer's Tau Platform (ATP)coreXingImaging was selected as the Imaging Core Lab for the Alzheimer's Tau Platform (ATP) Phase II clinical trial in the United States. The trial tests tau- and amyloid-targeted therapies for Alzheimer's disease involving up to 750 participants across approximately 78 sites, focusing on imaging biomarkers to evaluate treatment efficacy.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
XingImaging competitors and assessment
Company assessmentBroad incumbents
- ICON plc: Global CRO offering comprehensive clinical operations including imaging endpoint management. Comparable as an enterprise-scale alternative to XingImaging for sponsors seeking integrated trial services plus imaging core lab support.
- Parexel International: Large CRO with significant CNS/neuroscience trial experience and imaging endpoint services. Comparable for sponsors evaluating full-service CRO partners with established CNS trial infrastructure.
- Medpace: Mid-to-large CRO with CNS therapeutic area focus and growing imaging services. Comparable as an enterprise CRO alternative for neuroscience trial sponsors.
- IQVIA: Largest global CRO with imaging and biomarker capabilities across multiple therapeutic areas. Comparable as a one-stop-shop alternative for sponsors who may prefer bundling imaging with broader clinical operations.
Emerging players
- Avid Radiopharmaceuticals (Eli Lilly): Subsidiary of Eli Lilly developing florbetapir (Amyvid) and other PET imaging agents for Alzheimer's disease. Comparable as a CNS imaging radiopharmaceutical developer that sponsors and academic centers partner with for trial imaging.
Direct peers
- Bioclinica (now part of Clario): Provides medical imaging core lab services for clinical trials across multiple therapeutic areas. Directly comparable in imaging endpoint management, reader services, and image management SaaS for late-stage pharma trials.
- Cerveau Technologies: Develops and supplies tau PET imaging ligands (e.g., MK-6240, PI-2620) to pharma sponsors for Alzheimer's disease trials. Directly comparable as a radiopharmaceutical partner for CNS drug development programs where XingImaging provides imaging core lab services.
- Invicro (Clario): Clario's Invicro division is a direct competitor offering imaging core lab services, PET/SPECT biomarker analytics, and radiopharmaceutical development for CNS and oncology trials. Directly comparable to XingImaging across imaging CRO service lines and customer base.
- Life Molecular Imaging: Develops and manufactures PET radiopharmaceuticals for neurodegenerative disease imaging, including tau and amyloid tracers. Comparable as both a supplier/competitor for investigational radiotracers used in CNS clinical trials.
- Molecular Neuroimaging LLC: Imaging core lab and clinical research organization specializing in PET and SPECT neuroimaging for CNS clinical trials. Closely comparable in size, focus, and service offering to XingImaging's New Haven operation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
XingImaging social profiles
Digital presenceXingImaging compliance and trust
Trust signalCompliance1 record
XingImaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
XingImaging leadership team
Management profileNumber of profiles
Profiles3 records
XingImaging funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
XingImaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about XingImaging
What does XingImaging do?
XingImaging is a contract research organization that provides neuroimaging services for drug development and clinical research, specializing in the application of PET imaging with custom radiopharmaceuticals and radioligands for neurodegenerative and neuropsychiatric disorders. Its offerings span radioligand development and manufacturing, design and implementation of Phase 1 through Phase 4 clinical trials, and multi-center imaging core lab coordination, with a strong emphasis on investigational radiotracers and quantitative imaging outcome measures.
Is XingImaging a public or private company?
XingImaging is a private company. It is classified as corporate owned and is currently operating.
When was XingImaging founded?
XingImaging was founded in 2018. It employs 51 to 100 people.
Where is XingImaging based?
XingImaging is headquartered in Madison, United States, in the North America region.
How does XingImaging make money?
One revenue line is on record: clinical Imaging Services.
Who are XingImaging's main competitors?
Broad incumbents on record are ICON plc, Parexel International, Medpace and IQVIA. Avid Radiopharmaceuticals (Eli Lilly) is listed as an emerging player. Direct peers are Bioclinica (now part of Clario), Cerveau Technologies, Invicro (Clario), Life Molecular Imaging and Molecular Neuroimaging LLC.
Does XingImaging have an API?
No public API is recorded for XingImaging.
What industry is XingImaging in?
XingImaging's product category is Clinical Trial Imaging Services. Its primary akta.pro industry code is HLAGAEAH, Imaging Core Labs & Clinical Endpoint Adjudication, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 62151 and its SIC code is 8071.